Lilit Karapetyan

Hematology | Oncology
12902 Usf Magnolia Dr
Tampa, FL 33612

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications

Beyond Hospital Discharge: Defining Outpatient Care After Tumor-Infiltrating Lymphocyte Therapy.

Beyond Hospital Discharge: Defining Outpatient Care After Tumor-Infiltrating Lymphocyte Therapy.

Journal: JCO oncology practice
Published: September 04, 2026

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

Dual stimulation of CD40 and 41BB pathways during ex-vivo TIL expansion enhances CD8+ T cell expansion.

Journal: bioRxiv : the preprint server for biology
Published: August 01, 2026

Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma.

Nectin-4 as predictive biomarker of immune-related adverse event subtypes in adjuvant anti-programmed-death-1 treatment of melanoma.

Journal: Melanoma research
Published: April 08, 2026

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

iNOS is a key mediator of anti-PD-1 melanoma therapy response.

Journal: Frontiers in immunology
Published: March 23, 2026

Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.

Associations Between Pigmentation and the Clinicopathologic and Immune Landscape of Melanoma.

Journal: The American Journal of dermatopathology
Published: March 20, 2026

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Immunologic determinants of infusion products and the tumor microenvironment govern response to TIL therapy in advanced melanoma.

Journal: Med (New York, N.Y.)
Published: March 17, 2026

Measles Outbreak Driven by Nosocomial Transmission, Armenia, February-July 2023.

Measles Outbreak Driven by Nosocomial Transmission, Armenia, February-July 2023.

Journal: Emerging infectious diseases
Published: February 19, 2026

Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma.

Real-World, Evidence-Based, Retrospective Study of Patients Infused with Commercially Released Lifileucel for Advanced Melanoma.

Journal: Transplantation and cellular therapy
Published: February 05, 2026

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Melanoma brain metastases outcomes following nivolumab and relatlimab after ipilimumab and nivolumab progression.

Journal: Journal of neuro-oncology
Published: January 29, 2026

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Journal: Cancers
Published: December 29, 2025

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

ASO Visual Abstract: Recurrence and Survival Outcomes in Patients with Primary Merkel Cell Carcinoma with Positive, Negative or Not Performed Sentinel Lymph Node Biopsy.

Journal: Annals of surgical oncology
Published: December 08, 2025
Showing 1-12 of 53

Last Updated: 09/26/2026